NCT00045123

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence With Rising PSA Levels After Prostatectomy, Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Myrexis Inc. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer. PURPOSE: Randomized phase II trial to study the effectiveness of R-flurbiprofen in treating patients who have localized prostate cancer at risk of recurrence following radiation therapy and/or prostatectomy.

Detailed description

OBJECTIVES: * Determine the effect of R-flurbiprofen on time to systemic disease progression evaluated over a minimum of 3 years in patients with localized adenocarcinoma of the prostate with an intermediate or high risk of recurrence and rising prostate-specific antigen (PSA) levels after radiotherapy alone, prostatectomy alone, or both radiotherapy and prostatectomy. * Determine the effect of this drug on the change in serum PSA levels over time prior to androgen-deprivation therapy (ADT) in these patients. * Determine the effect of this drug on the time of initiation of ADT in these patients. * Determine the effect of this drug on the number of patients requiring ADT. * Determine the safety of this drug in these patients. * Determine the population pharmacokinetics of R-flurbiprofen and bioinversion of R-ToS in this patient population. * Determine the number of patients with systemic disease progression at the end of the study. * Determine the time to clinical disease progression in patients treated with this drug. * Determine the time to prostate cancer-related mortality and time to all cause mortality in patients treated with this drug. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to risk of recurrence based on Gleason score at diagnosis (5-7 vs 8-10). Patients are randomized to 1 of 3 treatment arms. * Arm I: Patients receive oral low-dose R-flurbiprofen twice daily. * Arm II: Patients receive oral high-dose R-flurbiprofen twice daily. * Arm III: Patients receive oral placebo twice daily. In all arms, treatment continues for up to 5.5 years (66 months) in the absence of disease progression or unacceptable toxicity. Patients who demonstrate increased prostate-specific antigen without objective disease progression and require androgen-deprivation therapy (ADT) continue receiving R-flurbiprofen. Patients who develop local recurrence or systemic disease may withdraw from study and receive additional therapy off study. PROJECTED ACCRUAL: Approximately 390 patients (130 per treatment arm) will be accrued for this study within 3 years.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	tarenflurbil
PROCEDURE	adjuvant therapy

Timeline

• Start date: 2002-02-01
• First posted: 2003-02-06
• Last updated: 2013-12-18

Locations

58 sites across 1 country: United States